[1] However, in a clinical trial, using monoclonal anti-CD4 antibody to selectively eliminate CD4+ T cells failed to reduce MS activity [2], which may be partially related to the fact that in addition to T helper 1 (Th1) and T helper 17 (Th17) cells, regulatory T cells (Tregs) also play a central role in MS pathogenesis by exerting potent anti-inflammatory activities. The gene discussed is CD4; the disease is myeloid sarcoma.